Table 1.

Baseline patient and tumor characteristics.

	All Patients (N = 80)		ctDNA-Negative (N = 54)		ctDNA-Positive (N = 26)		P
Median age (range)	48	25–85	48	25–70	52	28–85	0.537
Menopausal status							0.290
Pre	38	48%	28	52%	10	38%
Post	40	50%	25	46%	15	58%
Unknown^a	2	3%	1	2%	1	4%
Race							0.082
White	64	80%	45	83%	19	73%
Black	11	14%	8	15%	3	12%
Other	5	6%	1	2%	4	15%
Ethnicity							0.098
Not Hispanic	76	95%	53	98%	23	88%
Hispanic	4	5%	1	2%	3	12%
Germline BRCA1/2 mutation							0.743
No	62	77%	42	78%	20	77%
Yes	11	14%	8	15%	3	12%
Unknown^a	7	9%	4	7%	3	12%
T stage							0.128
1	13	16%	10	19%	3	12%
2	44	55%	33	59%	12	46%
3	19	24%	8	17%	10	38%
4	4	5%	3	6%	1	4%
Nodal status							0.079
Negative	48	60%	36	67%	12	46%
Positive	32	40%	18	33%	14	54%
TNM stage							0.029
I	11	14%	8	15%	3	12%
II	50	63%	38	70%	12	46%
III	19	24%	8	15%	11	42%
Neoadjuvant chemotherapy regimen							0.285
Anthracycline ± taxane	16	20%	8	15%	8	31%
Anthracycline/taxane/platinum	13	16%	9	17%	4	15%
Taxane/platinum	49	61%	36	67%	13	50%
Taxane	2	3%	1	2%	1	4%
Neoadjuvant immunotherapy							0.644
No	61	76%	42	78%	19	73%
Yes	19	24%	12	22%	7	27%
Surgery type							0.048
Lumpectomy	24	30%	29	37%	4	15%
Mastectomy	56	70%	34	63%	22	85%
Adjuvant radiotherapy							0.924
Yes	59	74%	40	74%	19	73%
No	21	26%	14	26%	7	27%
Adjuvant chemotherapy							0.877
Yes	39	49%	26	48%	13	50%
No	41	51%	28	52%	13	50%

Baseline patient and tumor characteristics.

P for continuous variables is Mann–Whitney U test. P for categorical comparisons is chi-square or Fisher–Freeman–Halton Exact test.

^aPatients with unknown status were excluded from statistical comparison.